On May 13, 2026, the FDA granted accelerated approval to sonrotoclax (Beqalzi) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. Beqalzi is a B-cell lymphoma 2 (BCL-2) inhibitor developed by BeOne Medicines (formerly BeiGene) and is the second BCL-2 inhibitor approved in the United States after venetoclax (Venclexta).
This coverage guide is for oncology access teams, specialty pharmacy professionals, payer strategists, and hematology pharmacists who need to understand Beqalzi's regulatory status, clinical evidence, accelerated approval implications, prior authorization requirements, and competitive positioning.
What Beqalzi is and how it differs from venetoclax
Beqalzi (sonrotoclax, BGB-11417) is a highly potent and selective BCL-2 inhibitor. Like venetoclax, it targets the BCL-2 protein that helps cancer cells evade apoptosis. However, sonrotoclax has been engineered for greater potency and a shorter half-life, which may reduce the risk of tumor lysis syndrome (TLS) and drug accumulation.
Key parameters:
| Parameter | Beqalzi (sonrotoclax) | Venclexta (venetoclax) |
|---|---|---|
| Class | BCL-2 inhibitor | BCL-2 inhibitor |
| Approved MCL indication | R/R MCL after ≥2 lines including BTK inhibitor | R/R MCL after ≥1 line (approved 2020) |
| MCL approval pathway | Accelerated approval | Full approval |
| Dosing in MCL | 320 mg oral once daily (after 4-week ramp-up) | 400 mg oral once daily (after 5-week ramp-up) |
| Ramp-up duration | 4 weeks | 5 weeks |
| Half-life | Shorter (less drug accumulation) | Longer |
| Manufacturer | BeOne Medicines | AbbVie / Genentech |
| MCL approval date | May 13, 2026 | June 2020 |
The shorter ramp-up period and reduced drug accumulation could give sonrotoclax a practical advantage in the outpatient setting, though head-to-head data against venetoclax in MCL are not available.
Clinical evidence: BGB-11417-201
The FDA accelerated approval was based on data from the phase 1/2 BGB-11417-201 trial (NCT05471843), a single-arm, open-label, multicenter study evaluating sonrotoclax in 103 adult patients with relapsed or refractory MCL who previously received anti-CD20-based therapy and a BTK inhibitor.
Efficacy results (as assessed by independent review committee using Lugano criteria):
- Overall response rate (ORR): 52% (95% CI, 42–62)
- Complete response (CR) rate: 16%
- Partial response rate: 37%
- Median time to response: 1.9 months (range, 1.6–6.2)
- Median duration of response: 15.8 months (95% CI, 7.4 to not estimable)
- Median follow-up: 14.2 months (range, 0.3–24.9)
Results were published in Blood and presented at the 2025 American Society of Hematology (ASH) Annual Meeting.
Safety profile:
- Sonrotoclax was generally well tolerated
- Serious adverse reactions occurred in 37% of 115 evaluable MCL patients
- Most frequent serious adverse reaction: pneumonia (10%)
- Treatment-emergent adverse events led to discontinuation in 13.9% of patients
Tumor lysis syndrome ramp-up protocol
Like venetoclax, sonrotoclax requires a dose ramp-up to mitigate tumor lysis syndrome (TLS) risk. The label specifies a four-week ramp-up:
| Week | Dose |
|---|---|
| Week 1 | 20 mg once daily |
| Week 2 | 80 mg once daily |
| Week 3 | 160 mg once daily |
| Week 4+ | 320 mg once daily (target dose) |
Access implications: The ramp-up protocol affects dispensing logistics. Specialty pharmacies must provide dose-escalation packaging and patient education materials. Access teams should verify that the ramp-up schedule is clearly documented in prior authorization submissions and that the full ramp-up kit is dispensed as a single fill rather than multiple prescriptions.
Accelerated approval obligations
Beqalzi received accelerated approval based on overall response rate and duration of response. Continued approval is contingent upon confirmation of clinical benefit in a confirmatory trial.
Confirmatory trial: CELESTIAL-RRMCL (NCT06742996) is currently ongoing. This trial must demonstrate a clinically meaningful endpoint — such as progression-free survival or overall survival — to convert the accelerated approval to full approval.
Access implications:
- Payers may impose reauthorization requirements tied to radiographic response assessments
- Some payers may reference the accelerated approval status as grounds for more restrictive coverage
- Access teams should proactively document response data at each reauthorization cycle to support continued coverage
Designations and regulatory context
- Breakthrough Therapy Designation (granted for R/R MCL)
- Priority Review
- Orphan Drug Designation (MCL, multiple myeloma, Waldenström macroglobulinemia, AML, MDS)
- Fast Track Designation (MCL and Waldenström macroglobulinemia)
- Reviewed under FDA Project Orbis (concurrent review with EMA as observer)
- NDA also under review in China by the National Medical Products Administration for both MCL and CLL/SLL
Prior authorization and formulary positioning
As a new oncology oral therapy with accelerated approval for a relapsed/refractory hematologic malignancy, Beqalzi will be managed under specialty pharmacy benefit designs.
Expected prior authorization criteria:
- Diagnosis of relapsed or refractory mantle cell lymphoma confirmed by pathology
- Documented prior treatment with at least two lines of systemic therapy including anti-CD20-based therapy and a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib)
- Prescribed by or in consultation with a hematologist or oncologist
- ECOG performance status documentation
- Baseline TLS risk assessment (tumor burden, lactate dehydrogenase, creatinine)
- Prescriber agrees to four-week ramp-up protocol with monitoring
Formulary tier expectation:
- Commercial plans: Specialty tier (Tier 4/5) with prior authorization; may require step therapy through venetoclax on some plans given its earlier MCL approval
- Medicare Part D: Specialty tier; prior authorization required; step edit through venetoclax possible
- Medicaid: Prior authorization required; state programs may require BTK inhibitor failure documentation
Step therapy considerations: Some payers may require a trial of venetoclax before approving sonrotoclax, since venetoclax has full FDA approval for MCL (broader label: after ≥1 prior therapy). Access teams should prepare to differentiate sonrotoclax based on its potency, shorter ramp-up, and trial-specific evidence in the post-BTK inhibitor population.
Expanded use and pipeline
Beqalzi is being investigated beyond MCL:
- CLL/SLL: CELESTIAL-TNCLL (BGB-11417-301, NCT06073821) is enrolling treatment-naïve CLL patients for sonrotoclax monotherapy. NDA also filed in China for R/R CLL/SLL
- Combination with zanubrutinib: A study (NCT07341191) is evaluating sonrotoclax plus zanubrutinib (Brukinsa, also from BeOne) in R/R MCL patients planned for standard-of-care CAR-T cell therapy
- Other B-cell malignancies: Sonrotoclax has shown promising activity across multiple B-cell malignancies in early studies
The sonrotoclax–zanubrutinib combination could eventually position BeOne as offering a dual-asset regimen for MCL and CLL, competing directly with AbbVie's venetoclax–acalabrutinib combination (approved for CLL in February 2026).
What to monitor next
- CELESTIAL-RRMCL confirmatory trial: Enrollment status and expected readout timeline for accelerated-to-full approval conversion
- NCCN guidelines update: Track whether NCCN adds sonrotoclax to MCL guidelines and at what category level
- Q3 2026 formulary reviews: First systematic payer coverage determinations after launch
- CLL/SLL regulatory submissions: Monitor U.S. filing for CLL/SLL, which would significantly expand the addressable population
- Sonrotoclax–zanubrutinib combination data: Could support a future combination regimen
- Real-world TLS monitoring: Post-marketing safety data on TLS rates with the four-week ramp-up protocol
- Venetoclax lifecycle: AbbVie has not actively pursued MCL label expansion for venetoclax; monitor competitive dynamics
Sources
- FDA: "FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma": https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sonrotoclax-relapsed-or-refractory-mantle-cell-lymphoma
- Hematology Advisor: "FDA Grants Accelerated Approval to Beqalzi for R/R Mantle Cell Lymphoma": https://www.hematologyadvisor.com/news/sonrotoclax-fda-approval-relapsed-mantle-cell-lymphoma
- CancerNetwork: "FDA Approves Sonrotoclax in Relapsed/Refractory Mantle Cell Lymphoma": https://www.cancernetwork.com/view/fda-approves-sonrotoclax-in-relapsed-refractory-mantle-cell-lymphoma
- ClinicalTrials.gov BGB-11417-201 (NCT05471843): https://clinicaltrials.gov/study/NCT05471843
- CLL Society: "FDA Approves Sonrotoclax for Mantle Cell Lymphoma": https://cllsociety.org/2026/05/fda-approves-sonrotoclax-for-mantle-cell-lymphoma
- Drugs.com Beqalzi FDA Approval History: https://www.drugs.com/history/beqalzi.html
- The ASCO Post: "High Response Rates With Front-Line Pivekimab Sunirine in BPDCN" (related hematology pipeline): https://ascopost.com/news/february-2026/high-response-rates-with-front-line-pivekimab-sunirine-in-bpdcn
